BioInsights - Update on the Latest Developments in Viral and Non-Viral Vector Manufacturing

Update on the Latest Developments in Viral and Non-Viral Vector Manufacturing

Guest Editor:

Jan Thirkettle, Chief Executive Officer at Transine Therapeutics

November 2018

Download full spotlight

Standardizing viral vector manufacture: maximizing production with the TRiP System^TM

D Farley

2 January 2019

Innovator Insight

Read more
Evaluation of Poros AAVX Pan-Affinity Resin for rAAV purification and cGMP Manufacturing

Daniel Hurwit, Scientist at Bristol-Myers Squibb

18 December 2018

Webinar

Watch now
Transmission Electron Microscopy: a Critical Component of the Vector Analytical Toolkit

V Carvalho

17 December 2018

Interview

Read more
Joined-up thinking: success criteria for tomorrow’s viral vector production platforms

P Vanek

17 December 2018

Podcast

Listen now
The latest developments in viral and non-viral vector manufacturing

J Thirkettle

10 December 2018

Foreword

Read more
The Growing Promise of Gene Therapy Approaches

J Grieger,

R Snyder,

J Samulski et al.

10 December 2018

Conference Insight

Read more
Update on the Sleeping Beauty transposon system for therapeutic applications

S Narayanavari

6 December 2018

Editorial

Read more
Joined-up thinking: success criteria for tomorrow’s viral vector production platforms

P Vanek

3 December 2018

Interview

Read more
Transmission Electron Microscopy: a Critical Component of the Vector Analytical Toolkit

V Carvahlo

3 December 2018

Podcast

Listen now
Lentiviral vectors in hematopoietic stem cell therapies: mainstay technology, or simply a bridge to gene editing?

M Moore,

J Counsell

30 November 2018

Editorial

Read more
AAV meets exosomes: at the cutting edge of cardiovascular gene therapy

R Hajjar

30 November 2018

Interview

Read more
Keeping viral vector manufacturing in-house: strategic considerations for gene therapy biotechs

T Miller

30 November 2018

Interview

Read more
Capacity or capability? Getting your priorities right in viral vector manufacturing

J Thirkettle

30 November 2018

Interview

Read more
Challenges and progress in lentiviral vector bioprocessing

E Macchiarulo,

P Bassett,

M Dudley

30 November 2018

Expert Insight

Read more
Applying learnings from the bioprocess development of Luxturna™

J Wright

30 November 2018

Interview

Read more
Scaling up gene therapy manufacturing for multinational pivotal trials & commercialization

K Regulski

30 November 2018

Interview

Read more
Scalable, helper virus-free AAV production with stable CAP-GT producer cell lines

Nicole Faust, CEO at CEVEC Pharmaceuticals GmbH

8 November 2018

Webinar

Watch now

CELL & GENE THERAPY INSIGHTS

Update on the Latest Developments in Viral and Non-Viral Vector Manufacturing

Sponsor

Co-sponsor

Standardizing viral vector manufacture: maximizing production with the TRiP SystemTM

Evaluation of Poros AAVX Pan-Affinity Resin for rAAV purification and cGMP Manufacturing

Transmission Electron Microscopy: a Critical Component of the Vector Analytical Toolkit

Joined-up thinking: success criteria for tomorrow’s viral vector production platforms

The latest developments in viral and non-viral vector manufacturing

The Growing Promise of Gene Therapy Approaches

Update on the Sleeping Beauty transposon system for therapeutic applications

Joined-up thinking: success criteria for tomorrow’s viral vector production platforms

Transmission Electron Microscopy: a Critical Component of the Vector Analytical Toolkit

Lentiviral vectors in hematopoietic stem cell therapies: mainstay technology, or simply a bridge to gene editing?

AAV meets exosomes: at the cutting edge of cardiovascular gene therapy

Keeping viral vector manufacturing in-house: strategic considerations for gene therapy biotechs

Capacity or capability? Getting your priorities right in viral vector manufacturing

Challenges and progress in lentiviral vector bioprocessing

Applying learnings from the bioprocess development of Luxturna™

Scaling up gene therapy manufacturing for multinational pivotal trials & commercialization

Scalable, helper virus-free AAV production with stable CAP-GT producer cell lines

Standardizing viral vector manufacture: maximizing production with the TRiP System^TM